Risk based development and manufacturing of biosimilars
The development of biosimilars presents a unique risk profile to biopharmaceutical companies
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
The development of biosimilars presents a unique risk profile to biopharmaceutical companies
The current era of rapidly evolving technology, market trends and policy is
Nine years after the passage of the biologics and biosimilars price competition
Biologics and biosimilar products are the fastest growing pharmaceutical products in the
Nanotechnology has already revolutionized disease prevention, diagnosis, and treatment, as evidenced by
Rare diseases hugely need moderate treatment choices. Vagrant medications have been ignored
In his book, “The End of History?”, published in the National Interest
Introduction & Objective: Different molecular weight forms of polyethylene oxide can be used
When preparing to launch a biosimilar, key distinctions from traditional biologic product
Biogas from biomass appears to have potential as an alternative energy source
Establishing a correlation between the in vitro dissolution profile of a Modified
A fundamental regulatory requirement of biosimilarity is that there are no clinically
Introduction: Breast cancer is the most common cancer and the second leading
To ensure product safety and efficacy, protein therapeutics must meet de ned
The biosimilars industry in the United States is still a nascent one
Uptake and acceptance of biosimilar medicines in the UK is accelerating and
In the USA only interchangeable products can be substituted for the reference
renal organic cation transporting (OCT)/multidrug and toxin extrusion proteins (MATEs), respectively. Successful bioanalysis of transporter biomarkers require suitably labelled reference standards, internal standards…
bioanalysis emerged as a critical tool in the process of drug discovery and development, and it is desirable the availability of less expensive, faster and simpler analytical methodologies to support
Regulatory requirements for biosimilars include process related impurities including (HCP) which should
This study described the functional characterization of a biosimilar rituximab and its
Proliferation and differentiation of stem cells requires a specific microenvironment âÂ?Â
The market for therapeutic proteins including biosimilars is steadily growing, resulting in
The demand for biosimilars and bioassays for biosimilars are increasing as the
The UK left the European Union on 23rd June 2016 but what
For authors and organisers
Find the right journal for your paper and submit your manuscript.